Drug Profile
GSK 1614235 / GSK 2330672
Alternative Names: 1614235 + 2330672; GSK 1614235/GSK 2330672; GSK 2330672/GSK 1614235Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics
- Mechanism of Action Sodium-bile acid cotransporter inhibitors; Sodium-glucose transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in USA (PO)
- 31 May 2012 Phase-I clinical trials in Type-2 diabetes mellitus (in volunteers) in USA (PO)